Genitourinary Oncology MRD Specialist

Natera; Orlando (FL); Sur place; USD 190 000 - 225 000; Plein temps

Avantages offerts par ce poste

Comprehensive benefits package

Résumé du poste

Natera seeks an experienced Clinical Oncology Specialist to join our GU Oncology sales team. This field-based role focuses on driving Signatera adoption across academic medical centers, hospital systems, and leading urology practices.

You will build relationships with GU Oncologists, Medical Oncologists, Pathologists, and other providers, educate them on Signatera's clinical uses and evidence, and work with cross-functional partners to expand territory performance. Travel 50–55% is expected.

Qualifications

• Bachelor's degree required.
• Minimum 5 years of demonstrated sales success in Oncology or related diagnostics.
• Experience calling on GU oncologists and academic medical centers preferred.
• Experience with molecular diagnostics or precision oncology is a plus.
• Willingness to travel 50–55%.

Responsabilités

• Develop and execute strategic territory plans to drive Signatera adoption.
• Educate providers on Signatera's clinical applications and evidence.
• Build relationships with GU oncologists, pathologists, and other stakeholders.
• Identify growth opportunities in academic medical centers and hospital networks.
• Collaborate with Core Oncology Sales, Marketing, and Medical Affairs.

Connaissances

Oncology sales

Urologic Oncology

Relationship building

Strategic account planning

Clinical knowledge (MRD/ ctDNA)

Cross-functional collaboration

Formation

Bachelor's degree

Outils

EMR systems

Description du poste

Natera seeks an experienced Clinical Oncology Specialist to join our GU Oncology sales team. This field-based role focuses on driving Signatera adoption across academic medical centers, hospital systems, and leading urology practices.

You will build relationships with GU Oncologists, Medical Oncologists, Pathologists, and other providers, educate them on Signatera's clinical uses and evidence, and work with cross-functional partners to expand territory performance. Travel 50–55% is expected.